--Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating

--Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating

MT Newswires · 05/11/2023 04:09

Please log in to view news